NLS Pharmaceutics Ltd. — FY2022 Form 20-F
Entity and period: The supplied filing is NLS Pharmaceutics Ltd.’s annual report for the fiscal year ended December 31, 2022, filed May 5, 2023. This differs from the request metadata naming Newcelx Ltd. and “2022 Q4.” The filing reports annual results, not standalone fourth-quarter results. Amounts below are in U.S. dollars unless noted.
Business context
NLS is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. Its lead candidate, Quilience (extended-release mazindol), is being developed for narcolepsy; Nolazol is a follow-on candidate for ADHD. NLS also describes early-stage candidates, including NLS-4. The company had no product approved for sale and no product-sales revenue in 2022.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $8.98 million | $5.92 million |
| General and administrative expense | $6.51 million | $5.94 million |
| Operating loss | $15.48 million | $11.86 million |
| Net loss | $16.50 million | $11.95 million |
| Basic and diluted loss per share | $0.84 | $1.00 |
| Net cash used in operating activities | $13.88 million | $14.94 million |
| Cash and cash equivalents at year-end | $8.95 million | $5.43 million |
| Total assets | $9.28 million | $5.76 million |
| Total liabilities | $6.00 million | $5.22 million |
| Shareholders’ equity | $3.28 million | $0.54 million |
Research and development expense rose 51.6%, principally reflecting the narcolepsy Phase 2 and open-label extension studies and drug-interaction work. General and administrative expense rose 9.5%. Net loss increased 38.1%, including a $0.92 million loss on extinguishment/conversion of convertible notes. No meaningful revenue-based margin can be calculated because the company had no product-sales revenue.
Year-end current assets were $9.25 million and current liabilities were $3.36 million, for working capital of approximately $5.89 million. The company reported $17.40 million of net financing cash flow in 2022, primarily from equity, warrant and note financing. The $704,160 insurance note payable was repaid; the $1.53 million short-term convertible notes were converted into shares and warrants in October. The balance sheet reports no outstanding note payable at year-end. Deferred revenue of approximately $2.50 million relates to the Eurofarma license payment and was not recognized as revenue.
Management expected available cash and financing access to fund at least one year of projected operations from the financial-statement issuance date. However, the audited notes state that ongoing losses and funding needs raise substantial doubt about the company’s ability to continue as a going concern beyond that one-year period. Additional capital will be required, and availability and terms are uncertain.
Material changes and financing
- Common shares outstanding increased from 16.22 million at December 31, 2021 to 32.43 million at December 31, 2022. The filing also reports 19.05 million warrants outstanding at year-end, creating potential dilution.
- 2022 financing included an April registered direct offering, an October private placement and note conversion, and a December $10 million private placement with BVF-affiliated funds. The BVF agreement also provided a conditional, BVF-discretionary right to purchase up to an additional $20 million in a second closing, subject to conditions.
- The company had a standby equity distribution agreement with up to $20 million nominal capacity, subject to limits and market conditions; it also had a reduced ATM capacity. These facilities do not assure that funds can be raised.
- Quilience’s Phase 2 trial enrolled 67 adults. The company reported statistically significant improvement in the primary excessive-daytime-sleepiness measure at weeks 1–4. The cataplexy comparison was not statistically significant in the randomized trial. Safety reporting included no serious or severe treatment-emergent adverse events, with dry mouth, nausea and decreased appetite among the more common events.
Outlook, risks, contingencies and unusual items
As of the report date, NLS said it intended to pursue Phase 3 development of Quilience, subject to regulatory agreement, and to seek expedited-development designations. The filing also reports that, on May 2, 2023, the FDA authorized the Phase 3 AMAZE program, comprising two planned placebo-controlled trials in adults with narcolepsy and cataplexy. This is a post-year-end development, not a 2022 result. Nolazol’s further ADHD development was on hold, and NLS described possible later Phase 3 work. NLS-4 remained preclinical.
- Clinical and regulatory risk: candidates may fail trials, require additional studies, or not receive FDA, EMA or other approvals. Quilience’s proposed reliance on the 505(b)(2) pathway and licensed historical data depends on regulatory acceptance and an adequate scientific bridge.
- Funding and going concern: continuing operating losses, negative operating cash flow and substantial future development costs make further financing necessary; financing could be unavailable or dilutive.
- Supply and manufacturing: the company relies on third parties, including a single mazindol supplier, has no manufacturing facilities, and reported no binding future supply arrangements. Manufacturing validation and regulatory approval remain relevant risks.
- Internal controls: management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2022. Reported weaknesses included reliance on outsourced accounting, insufficient U.S. GAAP-trained staff, inadequate segregation of duties, approval-documentation gaps and some unsupported expense reimbursements. Remediation was ongoing; the auditor did not attest to control effectiveness.
- Other risks: competition, controlled-substance compliance for mazindol, intellectual-property limitations, reimbursement and market acceptance, foreign-exchange exposure, and possible COVID-19-related disruption. NLS reported no material legal proceedings during the period and no intention to pay dividends in the foreseeable future.
- Unusual reporting discrepancies: the audited statements report FY2022 net loss of $16.50 million and accumulated deficit of $58.20 million, while portions of the narrative cite different figures. The cash-flow discussion also contains a net-loss figure inconsistent with the audited statements. Use the audited financial statements as the primary reported values and verify the discrepancies.
Most important facts for investors to verify
- Confirm the issuer and reporting period: the filing is for NLS Pharmaceutics Ltd. and FY2022, not Newcelx Ltd. or standalone Q4.
- Reconcile the narrative inconsistencies against the audited statements, especially net loss, accumulated deficit and operating cash flow.
- Assess cash runway and the availability, conditions and potential dilution of the BVF second closing, SEDA and other financing sources.
- Verify the status, design, endpoints, enrollment and results of the post-year-end Quilience Phase 3 program; do not treat planned or subsequent events as FY2022 performance.
- Track progress on mazindol supply, manufacturing validation and internal-control remediation, including whether controls become effective.
- Consider dilution from year-end shares, outstanding warrants, pre-funded warrants and the equity-plan reserve.